European Union (Withdrawal) Bill Debate
Full Debate: Read Full DebateLord Carlile of Berriew
Main Page: Lord Carlile of Berriew (Crossbench - Life peer)Department Debates - View all Lord Carlile of Berriew's debates with the Department for Exiting the European Union
(6 years, 10 months ago)
Lords ChamberI agree entirely with what has been said already by the noble Lords, Lord Hunt, Lord Warner and Lord Teverson, so I shall try to reduce the length of my remarks. I am puzzled about why we are here, and why we are here today at all. As to why we are here, we do not have to leave Euratom when we leave the European Union. There is absolutely no evidence that Euratom has performed other than well. It may well be that the Court of Justice of the European Union is the shibboleth, because it is related to Euratom and has jurisdiction over it, and our Government feel that because there is that connection our membership can be no more. But there are no cases about Euratom in the European Court of Justice, so Euratom has operated incredibly well.
I am puzzled as to why we are here today because there is another Bill before Parliament, the Nuclear Safeguards Bill, and, as has already been said, the first Committee day on it is tomorrow. I had assumed that we would be able to debate these issues as part of that Bill. After a three or four-day negotiation with the Public Bill Office I had to accept that that was not the case—so here we are today discussing Euratom, but not in the Nuclear Safeguards Bill, which deals with the nuclear safeguards relating to the products dealt with by Euratom. Alice could not have invented this situation.
I drafted Amendment 221, which is part of this group. There is nothing particular about the new clause in that amendment; it tries to do the same as all the other amendments and new clauses now being debated. It is clear that medical nuclear and radionuclear devices and products are extremely important. They save lives. For example, in University College Hospital and the Royal Free Hospital in London—I cite them because I have witnessed the process in those hospitals—every day of the week consideration is given to using these products to save the lives of patients suffering from cancer. All the arrangements for bringing those products into the United Kingdom are carried out under the umbrella of Euratom. It was not absolutely necessary for that to be done under the umbrella of Euratom, but it is what has happened. The noble Lord, Lord Teverson, mentioned the European Observatory on the Supply of Medical Radioisotopes. That is the umbrella organisation that supervises all these arrangements.
The noble Lord, Lord Henley, has been extremely helpful. As I have said in other debates, I am the patron of the Society for Radiological Protection, which contains more than 2,000 professionals who are engaged in various activities, including the use and safety of radioisotopes in the health service. The noble Lord, Lord Henley, as Minister, has answered many questions and had the courtesy to see the two senior members of the Society for Radiological Protection last week. He very kindly produced for me a list of questions with the Government’s original commentary and their additional commentary. It contains some gems, such as:
“We agree that continued engagement with ICRP”—
that is the International Commission on Radiological Protection—
“and IAEA will be important following UK exit from the EU and EURATOM”.
The trouble is that nothing has been done to ensure that that importance is translated into a process. The Government have said in one of these answers that they,
“will seek to maintain close and effective cooperation with Euratom on nuclear safety. This should include future discussions concerning development of Article 34 policy and cooperative structures”.
Well, hope springs eternal. Nothing has been done about that. I was told that,
“the Government is committed to ensuring that the UK regulatory regime covering radiation safety remains effective post-exit and can be updated in the future, including to take account of international best practice”.
Amen to that. Indeed, the Government are, “considering available options”—this year, next year. This is the flavour of the responses.
Then we have:
“The UK Government is seeking a bold and ambitious Economic Partnership with the EU that is of greater scope and ambition than any such existing agreement”.
It is Euratom plus, plus. The document continues:
“We want to have the greatest possible tariff- and barrier-free trade with our European neighbours”.
Noble Lords could have fooled me after the earlier debates this evening. It continues:
“The Government’s ambition is to maintain as many of these benefits as possible through a close and effective association with Euratom in the future”.
I mark that tomorrow and tomorrow and tomorrow. So the document goes on.
“The Government is seeking a bold and ambitious Economic Partnership with the EU that is of greater scope and ambition than any such existing agreement. We want to have the greatest possible tariff- and barrier-free trade with our European neighbours”.
I mark that as to boldly go where none has been before. There is only a little more, but it is instructive. This is about standards:
“HMG are working with BSI to ensure that our future relationship with the European Standards Organisations continues to support a productive, open and competitive business environment in the UK and for the continued benefit of UK patients”.
I mark that as “where angels fear to tread”. Finally:
“There will be regulatory systems in place for both medicines and medical devices after the UK has left the EU”.
Then we come to the important part:
“The future arrangements are a matter for the negotiations and it would not be appropriate to prejudge the outcome”.
That sounds a little bit like those kids’ films I used to see on Saturday mornings which ended with the words, “That’s all, folks”, but no real conclusion.
What has happened is that, despite the great attempts at co-operation by Ministers, we have absolutely no system in place, in draft or even in vision for the efficient importation and export of radiopharmaceutical products. We should not allow this legislation to go forward unless we know what plans the Government have, and unless we know that those plans have been discussed, negotiated and are the subject of agreement. Otherwise, there is only one option: let us stay in Euratom, which works very well.
Could the noble Lord address the issue raised by the noble Lord, Lord Teverson, about the notice of withdrawal under Article 106a? As a distinguished lawyer, is he of the opinion that Her Majesty’s Government could withdraw that notice unilaterally, which could be an issue of some moment if the Minister who is open to persuasive arguments were to form the view that the right course for the Government now is simply to withdraw the notice of withdrawal and seek to stay in Euratom?
If I could be allowed an ad majorem argument, I would recommend to noble Lords an article written on the Monckton Chambers website by the distinguished competition lawyer, George Peretz QC, which—as I understand it because I am not an expert on European law—provides the answer yes to the question put by the noble Lord, Lord Adonis.
My Lords, I have two amendments which are grouped with Amendment 8. I am afraid that they probably should not have been included, but like the noble Lord, Lord Teverson, and my noble friend Lord Liddle, I was in Brussels today and did not have a chance to argue the groupings, so I am afraid that noble Lords are going to have to hear me speak on this issue tonight. My Amendment 114 makes a rather important cross-reference to Euratom.
The amendment seeks essentially to add a clause to the Bill after Clause 7, with an accompanying schedule. Before we understand what is happening to our whole regulatory system and therefore pass this Bill, and certainly before we leave the European Union, we need to know from the Government what their view is on future relationships with the EU executive agencies. The schedule lists those agencies which include two Euratom agencies. It lists the supply agency to which the noble Lord, Lord Teverson, referred. Its observatory plays a key role in dealing with supply chains of extraordinarily sensitive and potentially dangerous material. It lists also the Fusion for Energy agency which deals with some of the aspects to which the noble Lord, Lord Broers, referred in terms of the development of fusion as a new source of energy and the high-level, European-wide research programme at Culham and elsewhere. They are very important agencies. At this point we do not know what future UK participation, arrangements, observer status or links with those agencies are going to be.
In addition to those two Euratom agencies, there are 34 executive agencies of the European Union. I have noticed the time and I will therefore not go through the role and remit of them all, as well as the importance of knowing where we are, but they include a number of agencies of great importance to the lives of our citizens, to our industry and to our environment. There are agencies which deal with safety at work, food safety, environmental safety generally, and of course there is the EU Medicines Agency, which regrettably is moving away from Britain, dealing with medical safety. There is a whole range dealing with police and judicial procedures.
These agencies are not law-making bodies, but they are operationally very important to the sectors to which they apply. The UK has engaged very effectively with most of those agencies, to the benefit of our citizens, industries, sciences and judicial system. I have asked a number of Written Questions as to what the future arrangements are, with the standard reply being: “This will all be sorted out in the negotiations”. However, the negotiations are going on at the same time as we are dealing with the Bill. We need to know, in relation to the Bill, how those agencies will interact with the regulations newly transposed into UK law and the way in which we operate in those industries and systems.
My visit to Brussels in the last couple of days has underlined the urgency of the situation of knowing where we are with such agencies. For the first time, I carefully read the EU’s proposition on how we deal with transition periods. That document says that the UK will not only no longer participate in the institutions of the European Union but also,
“no longer participate in … the decision-making or the governance of the Union bodies, offices and agencies”.
In other words, in approximately one year and 34 days, we will no longer participate in any of these vital agencies. It is possible, if the Government put their mind to it, to establish in that period new relationships. In some of these agencies, non-EU bodies are either observers or participants. At the moment, we have not a clue how the Government are approaching the future in all of these important areas. It is an urgent decision that we cannot delay until the end of the transition period, because unless the Government persuade the EU otherwise in the next few weeks and months, from the date of exit we will no longer participate. This will change the way in which we operate in a range of safety, environmental, scientific, judicial and police areas—including security and defence.
That issue arises for a whole number of areas well beyond Euratom. On Euratom, I agree very much with what virtually everybody else has said: it is unnecessary to come out of Euratom. It is still possible to distinguish our approach to Euratom and effectively rescind our resignation from it without changing our position on the EU. Indeed, all the arguments—from industry, science and environmentalists—indicate that we should do that. At the same time, I urge your Lordships, and the Government in particular, that before we get very far in the process on the Bill, we should get a clear indication, not only on the Euratom agencies, but on the rest of the agencies set out in Amendment 263 proposing a new schedule, so that we will know, well in advance of leaving the European Union and its agencies and well in advance of the beginning of the transition period, quite how we will operate with them in future. I ask the Minister to take seriously the list I have given him and, perhaps in writing or on Report, to indicate to us how the Government intend to deal with this very important tissue.
I am grateful to the Minister for the explanation that he has given on the issue of medical isotopes. Can he give us one further piece of information? How many meetings have actually taken place so far in an attempt to negotiate with the EU the continuity of the system of importing and exporting medical isotopes from the UK and from the EU?
I am afraid I do not have those figures to hand. I cannot tell him how many meetings there have been.
I can say that there has been extensive dialogue and discussion with both our EU partners and international partners at official and ministerial level. I can write to him with the exact number, which I can discover.